We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01559922
Recruitment Status : Completed
First Posted : March 21, 2012
Results First Posted : February 14, 2017
Last Update Posted : November 1, 2019
ethica Clinical Research Inc.
Information provided by (Responsible Party):
Suneva Medical, Inc.

Brief Summary:
The purpose of this study is to determine whether Artefill is safe and effective for the correction of atrophic facial acne scars.

Condition or disease Intervention/treatment Phase
Atrophic Acne Scar Drug: Normal Saline Device: Artefill Phase 3

Detailed Description:

This is a multi-center, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of Artefill for correction of moderate to severe atrophic acne scars.

The study is divided into two study periods. In Period I, scars meeting the treatment criteria will be individually identified, numbered and mapped using photographs and transparent sheets prior to treatment. This mapping will be used to track individual scars throughout the trial. Four (4) weeks following a baseline qualification visit, subjects randomized to treatment will receive one treatment of Artefill or Control (saline), administered by the Treating Investigator. At 72 hours following injections, subjects will be followed-up by telephone to confirm the occurrence of any AEs. Subjects will return to the clinic at 2 weeks for follow-up evaluation, and then at 4 weeks where subjects may receive one optional touch-up treatment. Subjects receiving touch-up treatment will be followed-up by telephone at 72 hours to confirm the occurrence of any AEs, and return for clinic visits at 6 weeks and 8 weeks. All subjects will then return for clinic follow-up at months 3 and 6 (after last treatment).

Period II is open label and will begin at month 6. Artefill group subjects will return to the clinic for assessments at months 9 and 12 (Track A) and Control group subjects will enter Track B, re-establish baseline, and complete additional month 6 visit activities including Artefill treatment. Subjects will receive touch up (if required) 4 weeks later, and be followed for an additional 12 months.

Subjects will be required to abstain from other aesthetic treatment to their face during the study period and failure to do so will be considered a protocol violation. However, if a subject does receive additional aesthetic or non-aesthetic treatments, available information on such treatment will be collected and the subject will be continued to be followed per protocol. Such subjects will not be excluded from the analysis, but will also be evaluated separately.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 175 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized Placebo-Controlled Double-Blind Study of the Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction
Study Start Date : February 2012
Actual Primary Completion Date : April 2013
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Scars

Arm Intervention/treatment
Placebo Comparator: Placebo
Normal Saline
Drug: Normal Saline
Administration of up to 2 study treatments administered 6 weeks apart

Experimental: Artefill
Dermal Filler
Device: Artefill
Administration of up to 2 study treatments administered 6 weeks apart

Primary Outcome Measures :
  1. ASRS Responder Rate at 6 Months [ Time Frame: 6 months post-treatment ]
    Subject considered to be a "responder" if at least 50% of treated scars demonstrate an ASRS improvement of ≥ 2-point (Blinded Evaluator assessment).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject must be an outpatient, male or female subjects of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study.
  2. Subject must have moderate to severe atrophic acne scars
  3. Subject must desire correction of his/her moderate to severe acne scarring.
  4. Subjects of all Fitzpatrick skin types are eligible.
  5. Subject must be willing to withhold additional aesthetic therapies to the face (eg, other soft tissue fillers: Restylane, Radiesse, Sculptra, and/or any resurfacing procedures for the duration of the study.
  6. Subject must be able to follow study instructions and likely to complete all required visits, as assessed by the Investigator.
  7. Subject must sign an IRB-approved Informed Consent form, Photographic Release Form, and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study-related procedures being performed

Exclusion Criteria:

  1. Female subjects that are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
  2. Undergo facial treatments with any listed of the prohibited treatment/procedures and/or use of any other prohibited treatment/procedure within certain time periods.
  3. Have any skin pathology or condition that could interfere with the evaluation of the treatment areas, worsen due to the proposed treatment or require interfering topical, systemic or surgical therapy.
  4. Have a recent or current history of inflammatory skin disease, infection, cancerous/pre-cancerous lesion, unhealed wound or clinically significant acne in the proposed treatment areas. Clinically significant acne is defined as a patient whom has >3 active inflammatory acne lesions in either the right or left treatment area.
  5. Have a history of systemic granulomatous diseases active or inactive (eg, Sarcoid, Wegeners, TB, etc.) or connective tissue diseases (eg, lupus, dermatomyositis, etc.).
  6. Have hypertrophic acne scars, any evidence of keloid scarring, predominantly icepick scarring (defined as more than half of all scar area in either the left or right or treatment area) or sinus tract scars.
  7. Have a known hypersensitivity or previous allergic reaction to any of the components of the study device (including lidocaine or any amide-based anesthetic), or has a history of allergies to any bovine collagen products, including but not limited to injectable collagen, collagen implants, hemostatic sponges, and collagen-based sutures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01559922

Layout table for location information
United States, California
Call Suneva for Info
Beverly Hills, California, United States, 90210
Call Suneva for Info
Los Angeles, California, United States, 90036
Call Suneva for Info
San Diego, California, United States, 92121
Call Suneva for Info
Santa Monica, California, United States, 90404
United States, Florida
Call Suneva for Info
Miami Beach, Florida, United States, 33137
Call Suneva for Info
Saint Petersburg, Florida, United States, 33716
United States, Maryland
Call Suneva for Info
Glenn Dale, Maryland, United States, 20769
United States, Massachusetts
Call Suneva for Info
Wellesley, Massachusetts, United States, 02481
United States, Texas
Call Suneva for Info
Houston, Texas, United States, 77056
United States, Washington
Call Suneva for Info
Spokane, Washington, United States, 99204
Sponsors and Collaborators
Suneva Medical, Inc.
ethica Clinical Research Inc.
Layout table for investigator information
Study Director: Nancy Serreta Suneva Medical
Layout table for additonal information
Responsible Party: Suneva Medical, Inc.
ClinicalTrials.gov Identifier: NCT01559922    
Other Study ID Numbers: SUN-11-001
First Posted: March 21, 2012    Key Record Dates
Results First Posted: February 14, 2017
Last Update Posted: November 1, 2019
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Suneva Medical, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathological Conditions, Anatomical
Polymethyl Methacrylate
Vasodilator Agents
Antimutagenic Agents
Protective Agents
Physiological Effects of Drugs